about
Planar Tc99m--sestamibi scintimammography should be considered cautiously in the axillary evaluation of breast cancer protocols: results of an international multicenter trialAttenuation correction for lung SPECT: evidence of need and validation of an attenuation map derived from the emission data.New exercise-dipyridamole combined test for nuclear cardiology in insufficient effort: appropriate diagnostic sensitivity keeping exercise prognosis.Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.(18)F-FDG PET-CT for Staging of Conjunctival Melanoma.Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model.Fab(nimotuzumab)-HYNIC-99mTc: Antibody Fragmentation for Molecular Imaging Agents.(99m)Tc glucarate as a potential radiopharmaceutical agent for assessment of tumor viability: from bench to the bed side.Predictive value of (99m)Tc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer.[(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model.Synthesis and evaluation of (99m)Tc chelate-conjugated bevacizumab.99mTc-HYNIC octreotide in neuroblastoma.Dobutamine modulated Tc-99m MIBI scintigraphy in secondary hyperparathyroidism in uremic patients.177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.(68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin.Early Detection of Bone Metastasis in Small Cell Neuroendocrine Carcinoma of the Cervix by 68Ga-DOTATATE PET/CT Imaging.In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer.Synthesis of 99mTc-nimotuzumab with tricarbonyl ion: in vitro and in vivo studies.Incidental focal colonic uptake in studies 18F-FDG PET/CT.99Tcm-sestamibi uptake by malignant melanoma lesionsDouble-phase scanning of the thyroid gland with Tc-99m MIBI in a patient with a malignant nodule. A case of tracer redistribution?[Examination of regional limph nodes in penile carcinoma by 99M Tc-MIBI scintigraphy]Regional ganglionar metastasis 24 years after surgical resection of a malignant melanoma99Tc(m)-MIBI scanning of the thyroid gland in patients with markedly decreased pertechnetate uptakeComparison of 99mTc-MIBI scintigraphy and sentinel node biopsy in the detection of occult lymph node metastases from cutaneous melanomaScintigraphic evaluation of malignant melanoma lesions with Tc-99m tetrofosminStaging of regional lymph nodes in melanoma patients by means of 99mTc-MIBI scintigraphy[Value of radioguided surgery with dobutamine 99mTc-MIBI in persistent secondary hyperparathyroidism]Preparation and primary bioevaluation of 99mTc-labeled-1-thio-β-D-glucose as melanoma targeting agentDevelopment of 99mTc(CO)₃-dendrimer-FITC for cancer imagingTc-99m- and Ga-68-labeled somatostatin analogues in the evaluation of Hurthle cell thyroid cancer68Ga-PSMA and 11C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttleQuantitative comparison between single-photon emission computed tomography and positron emission tomography imaging of lung ventilation with 99mTc-technegas and 68Ga-gallgas in patients with chronic obstructive pulmonary disease: A pilot studyIs True Whole-Body 18F-FDG PET/CT Required in Pediatric Lymphoma? An IAEA Multicenter Prospective StudyIntraindividual comparison of 68Ga-DOTATATE PET / CT vs 11C-Choline PET / CT in patients with prostate cancer in biochemical relapse: in vivo evaluation of the expression of somatostatin receptors
P50
Q24811103-32D0B97E-C577-46E8-B68D-DACA12BEAC32Q33411811-5B79E7FC-6690-44A8-823A-9F6827329A36Q36024228-14B7DE8F-EB79-4207-8CAC-304C926226DEQ37100372-9C10A992-D4A9-4C16-9DF7-FB25748B7D82Q39364421-33D42FBE-B968-4EC5-96DE-55EEDA9DE594Q39593800-BE396091-B219-4DBF-9C17-66418BE07AF3Q39933613-378E59CB-0A0A-4153-81CA-1A3F6A47BBAAQ42129354-8D073A8E-ADC9-441D-B69F-8BBD37BA5E2CQ44068743-D00D0FE0-06F9-471F-8263-85425305AB46Q44448280-C90473F7-D58C-4C72-BDC7-1FC80DCCABB6Q45094429-07F42710-57C1-45ED-A808-0558B4C58525Q46224711-940D352E-E085-47EE-BEEF-90922C4E0AF5Q46989074-96C26580-4AE8-43D7-BB53-1C9F15D14DBAQ47602120-EE80521A-1195-45DF-BF38-C63D128E034DQ48860405-55323727-96E0-4127-9C31-2071EBDA3C36Q52957391-69C49807-AC0B-4A41-BE72-7E3DA274B92BQ53198621-F86FB74E-358A-4169-8DA5-B60DB23B7CF1Q54550808-CEB1EC8D-A15B-4E27-959C-6CAC1311D77FQ54598195-85F22161-DDDB-4ABB-8568-B0F833C24391Q73037827-76BEB53B-4C81-4EC5-B52F-E1756EBF2A23Q73438786-27A1F9D2-B773-40D3-9599-5E3BD1BD2CC9Q73626819-5237890A-BD0F-4EAE-8FE7-87C0B329C439Q74379628-2FA73EDF-EADB-4D1B-9D24-6C7A5A629DB7Q74643882-CDE01D04-96C3-4995-82DA-4456AB7D1C03Q75205168-9063C909-EE22-4224-9E54-887A8B7079E6Q77469248-5FD77581-7EE8-49D3-9318-37F4798ABD30Q79125654-DA8A2D02-7C13-4403-84F6-67D877AC0617Q79437459-B5C8202C-7CFF-4ECB-922A-ACA893AA15B0Q83143409-69557A77-EA03-4B1D-A3B2-FBD49B5C8199Q84582465-314BA911-7BBD-4FD6-BEE7-6F7E73B7B513Q84722874-C00BDE09-4A0F-4246-B033-765984995C3DQ88757249-D766D0FA-8D66-425F-B93C-26B070491E8BQ90087032-9A3EC35F-8039-44E8-A5CD-513B007C81A5Q91228917-99BC3B20-4E24-4725-9A8E-DADF2DA7B32BQ93158693-3D3AF00F-D2F8-4267-82F6-79778C5D5F31
P50
description
researcher
@en
name
Alonso O
@nl
Omar Alonso
@en
type
label
Alonso O
@nl
Omar Alonso
@en
altLabel
Alonso O
@en
prefLabel
Alonso O
@nl
Omar Alonso
@en
P106
P31
P496
0000-0002-7491-1144